Want to see FR:VETO full AI Analyst Report?
Top Page
VETOQUINOL
(VETO)
Select Model
Select Model
Rating:74Outperform
Price Target:
€81.00
▲(12.81% Upside)
Action:Upgraded
Date:08/10/26
The score is driven primarily by solid financial quality—especially the low-debt balance sheet and steady profitability—tempered by weak/flat revenue momentum, questions around the sustainability of the 2025 margin jump, and uneven cash conversion. Technicals are neutral with only partial trend strength, while valuation is reasonable with a modest dividend.
Positive Factors
Conservative balance sheet
A very low leverage profile materially reduces refinancing and solvency risk, preserving capital flexibility. Over a multi-quarter horizon this supports steady investment in R&D and manufacturing, cushions cyclical animal-health demand swings, and underpins shareholder distributions.
Negative Factors
Weak revenue momentum
Flat-to-declining top-line reduces the potential for operating leverage and constrains long-term earnings growth. Without sustained revenue expansion, the company may need higher margin or share-buyback reliance to grow EPS, limiting strategic optionality over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
A very low leverage profile materially reduces refinancing and solvency risk, preserving capital flexibility. Over a multi-quarter horizon this supports steady investment in R&D and manufacturing, cushions cyclical animal-health demand swings, and underpins shareholder distributions.
Read all positive factors
VETOQUINOL (VETO) vs. iShares MSCI France ETF (EWQ)
Market Cap
€810.09M
Dividend Yield1.38%
Average Volume (3M)10.39K
Price to Earnings (P/E)14.2
Beta (1Y)0.41
Revenue Growth-2.51%
EPS Growth-1.20%
CountryFR
Employees2,454
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.82
Shares Outstanding11,881,902
10 Day Avg. Volume9,178
30 Day Avg. Volume10,395
Financial Highlights & Ratios
PEG Ratio-21.04
Price to Book (P/B)1.68
Price to Sales (P/S)1.89
P/FCF Ratio19.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.38
Revenue Forecast (FY)€512.60M
VETOQUINOL Business Overview & Revenue Model
Company Description
Vetoquinol S.A. is a prominent veterinary pharmaceutical enterprise dedicated to the innovation, development, and global commercialization of both medicinal and non-medicinal solutions for animal health. Its operations extend across Europe, the Am...
How the Company Makes Money
Vetoquinol makes money primarily by selling animal health products (veterinary medicines and related health products) to customers in the veterinary and animal production value chain. Revenue is generated from (1) sales of proprietary (brand) prod...
VETOQUINOL Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
64
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 525.70M | 539.20M | 529.27M | 539.78M | 521.27M |
| Gross Profit | 160.36M | 387.45M | 291.38M | 172.37M | 167.37M |
| EBITDA | 348.90M | 114.08M | 112.33M | 103.46M | 116.86M |
| Net Income | 57.30M | 58.69M | 55.56M | 47.99M | 62.86M |
Balance Sheet | |||||
| Total Assets | 763.63M | 744.13M | 692.23M | 651.85M | 624.56M |
| Cash, Cash Equivalents and Short-Term Investments | 221.08M | 206.33M | 147.46M | 93.71M | 69.00M |
| Total Debt | 15.29M | 21.12M | 17.63M | 17.42M | 15.38M |
| Total Liabilities | 172.19M | 168.20M | 165.12M | 167.19M | 183.21M |
| Stockholders Equity | 591.37M | 575.84M | 527.01M | 484.57M | 441.26M |
Cash Flow | |||||
| Free Cash Flow | 51.35M | 68.15M | 70.38M | 39.90M | 56.76M |
| Operating Cash Flow | 72.08M | 85.83M | 89.39M | 62.39M | 89.17M |
| Investing Cash Flow | -20.56M | -15.65M | -18.88M | -21.52M | -33.45M |
| Financing Cash Flow | -25.08M | -16.03M | -15.50M | -16.06M | -120.31M |
VETOQUINOL Technical Analysis
Negative
71.80
Price Trends
71.36
Negative
71.98
Negative
76.12
Negative
Market Momentum
-0.59
Positive
35.49
Neutral
14.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VETO, the sentiment is Negative. The current price of 71.8 is above the 20-day moving average (MA) of 70.66, above the 50-day MA of 71.36, and below the 200-day MA of 76.12, indicating a bearish trend. The MACD of -0.59 indicates Positive momentum. The RSI at 35.49 is Neutral, neither overbought nor oversold. The STOCH value of 14.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:VETO.
VETOQUINOL Peers Comparison
UnderperformOutperform
Sector (55)
FR:VETO
VETOQUINOL
67.60
-4.32
-6.00%
FR:VIRP
Virbac SA
314.00
-9.57
-2.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.